Michael P. Barrett

TL;DR: The meaning of “resistance” related to leishmaniasis and its molecular epidemiology are discussed, particularly for Leishmania donovani that causes visceral leish maniasis, and how resistance can affect drug combination therapies are discussed.

TL;DR: Financial constraints continue to represent a major hurdle to drug development, however, the appearance of not-for-profit product-development partnerships offers a new paradigm for bringing new drugs to patients.

TL;DR: The challenges of chemotherapy for human African trypanosomiasis (HAT) are discussed, and the few drugs registered for use against the disease are unsatisfactory for a number of reasons.

TL;DR: It is demonstrated that a retention time prediction model can improve metabolite identification on a hydrophilic interaction chromatography-high-resolution mass spectrometry metabolomics platform, allowing identified metabolites to be mapped onto an organism-wide metabolic network, providing opportunities for future studies of cellular metabolism from a global systems biology perspective.

TL;DR: IDEOM provides a user-friendly data processing application that automates filtering and identification of metabolite peaks, paying particular attention to common sources of noise and false identifications generated by liquid chromatography-mass spectrometry platforms.